Drug‑price sting goes viral

A pharmacy worker tapped one button and turned a prescription from about $4 to $97, then tapped another and brought it back down. The clip spread because it showed, in one screen, how a person with insurance can sometimes be charged more than a cash customer standing at the same counter. (ftc.gov) That sounds backwards, but it is a real feature of the United States drug-pricing system. Your insurance price is not “the price”; it is the result of contracts among the pharmacy, the insurer, and a company called a pharmacy benefit manager that sits in the middle and sets many of the terms. (kff.org) A pharmacy benefit manager is the traffic cop for prescription benefits. It decides which drugs are preferred, what the pharmacy gets paid, what the patient owes at the register, and which pharmacies are in the network. (rheumatology.org) The three biggest pharmacy benefit managers — Caremark, Express Scripts, and Optum Rx — control more than 80 percent of the market, and each is tied to a giant health company with its own insurer or pharmacy business. That is why one billing rule can affect millions of people at once. (oversight.house.gov) The Federal Trade Commission said in July 2024 that these middlemen may be “inflating drug costs” and squeezing neighborhood pharmacies. In January 2025, the agency said the biggest firms marked up dozens of specialty generic drugs by hundreds or thousands of percent and generated more than $7.3 billion in revenue over six years. (ftc.gov 1) (ftc.gov 2) One common trick is called spread pricing. That means the middleman charges the health plan one amount, pays the pharmacy a lower amount, and keeps the gap as profit. (ncpa.org) Another reason the insured price can look absurd is that discount cards and cash programs run on a separate lane from insurance. GoodRx says its coupons cannot be combined with insurance, and its listed price can beat a copay because it is using a different contract than the one attached to your health plan. (goodrx.com) (nerdwallet.com) Insulin is the most explosive example because people do not buy it once and forget it. Medicare now caps covered insulin at $35 a month under Part D drug coverage, and 25 states plus the District of Columbia have caps for some state-regulated commercial plans, but those caps limit what the patient pays, not the hidden price negotiations underneath. (medicare.gov) (diabetes.org) (kff.org) Federal regulators have already moved from reports to court. In September 2024, the Federal Trade Commission sued Caremark, Express Scripts, and Optum Rx, saying their rebate system artificially inflated insulin list prices and pushed patients toward higher-cost products. (ftc.gov) That case has not produced a clean ending. A judge let the suit move forward in early 2025, but by April 2026 the Federal Trade Commission had paused parts of the case, even as settlements were being discussed or reached with some firms. (healthcaredive.com) (axios.com) (fiercehealthcare.com) The reason the video hit so hard is that it turned a hidden spreadsheet war into a number anyone could understand. When a clerk can make a medicine jump from $4 to $97 with a billing toggle, people stop hearing “complex system” and start hearing “someone built it this way.” (ftc.gov)